Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Craneware revenue growth accelerates in first half

(Sharecast News) - Healthcare software specialist Craneware said in a trading update on Wednesday that it saw accelerated revenue growth in the six months ended 31 December, reflecting an improving market environment as US hospitals and healthcare institutions refocussed their strategic goals. The AIM-traded firm said revenue jumped 8% to $91m, aligning with its expectations.

Adjusted EBITDA also rose 8%, reaching around $27.5m, up from $25.5m in the first half of the 2023 financial year.

Despite sales success yet to be converted into revenue, annual recurring revenue (ARR) increased about 3% to $171.4m, as the company maintained a net revenue retention rate of 100%.

Craneware said it had continued to employ its cash reserves to reduce debt and interest costs, resulting in lower interest rate charges.

That, coupled with growth in the period, led to a return to growth in adjusted earnings per share, with a 3% increase, compared to the 6% decrease seen in the same period a year earlier.

The company said it maintained a robust financial position, with total bank debt reduced to $59.2m from $107.9m year-on-year, while total cash reserves slid to $63.9m from $90.8m.

Its board said it had decided to extend the share buyback programme, originally set to expire on 17 January, for an additional three months to 17 April under the same terms as previously announced.

Looking ahead, Craneware said its investments in the Trisus platform, as well as the recent launch of optimisation suites and innovative partnerships, positioned it strongly for the second half of the year.

The firm said it anticipated benefiting from growing confidence in its market, and saw substantial new opportunities to support its customers in delivering better value in US healthcare.

"With US healthcare and our hospital customers re-focusing on the future, the drive to better value in healthcare has returned to the forefront of their strategic priorities and we are pleased to see the returning confidence having a positive impact on our financial results," said chief executive officer Keith Neilson.

"The importance of digitalisation, to meet these challenges, has never been clearer.

"With approximately 40% of all US hospitals as customers, our considerable data assets and expanded offering allow us to derive meaningful insights for them to improve their operational efficiency, ensure their financial strength and continue to deliver outstanding care to their communities."

Craneware said it would release its results for the six months ended 31 December on 4 March.

At 1352 GMT, shares in Craneware were up 1.77% at 1,837p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Goldman Sachs to scrap bonus cap for UK dealmakers
(Sharecast News) - Goldman Sachs will remove a cap on bonuses for its London-based staff, according to Sky News, with the firm now set to resume making multi-million-pound payouts to its top-performing traders and dealmakers.
Gazprom swings to $6.9bn loss as Europe sales plunge
(Sharecast News) - Russia's natural gas heavyweight Gazprom swung to huge loss in 2023 after sales to Europe dropped due to Western sanctions on Moscow.
London cabbies launch £250m legal action against Uber
(Sharecast News) - Uber Technologies is facing legal action on behalf of more than 10,500 London black cab drivers, it was confirmed on Thursday.
Peloton announces CEO departure; to cut 15% of workforce
(Sharecast News) - Peloton announced the departure of its chief executive on Thursday, alongside plans to cut around 15% of its workforce amid a restructuring programme aimed at reducing annual expenses by more than $200m.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.